ArticleHeliyon2024
Functionalization of β-cyclodextrin metal-organic frameworks with gelatin and glutamine for drug delivery of curcumin to cancerous cells.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Development of a 3D collagen type I hydrogel scaffold for modeling hyperglycemia-induced spinal neuronal damage and therapeutic evaluation.Histochemistry and cell biology · 2026Article
- Biopolymer-mediated metallic nanomaterials: recent advancements, current challenges and future outlooks.RSC advances · 2026Review
- Modulation of Drug Release in Anticancer Therapy: Recent Advances, Challenges, and Emerging Drug Delivery Platforms.Pharmaceutics · 2026Review
- Curcumin Delivery Systems: From Importance and Microencapsulation Techniques to Molecular Docking and Dynamics for Rational Formulation Design.Topics in current chemistry (Cham) · 2026Review
- Cyclodextrin-based MOFs for oral delivery of fingolimod with enhanced pharmacokinetics.Drug delivery and translational research · 2026Article
- Development of β-CD metal organic frameworks loaded with olaparib: a novel approach for the treatment of cervical cancer.Scientific reports · 2026Article
- From Amino Acids to Proteins: Biomolecular Nanostructures as Closed-Loop Platforms for Tissue Engineering and Drug Delivery.ACS nanoscience Au · 2026Review
- Multifunctional Metal-Organic Frameworks for Enhancing Food Safety and Quality: A Comprehensive Review.Foods (Basel, Switzerland) · 2025Review
- Vitexin as a Potential Antidysmenorrheic Agent: Development of a ZIF-8-Based Immediate-Release System and Evaluation via In Vivo and In Silico Approaches.Biomedicines · 2025Article
- Bioinspired synthesis of ultra-small copper-aspartate BioMOF nanodots using sodium caseinate for targeted curcumin delivery.Scientific reports · 2025Article
- Enhanced Encapsulation of Linalyl Acetate in Cyclodextrin-Based Metal-Organic Frameworks for Improved Stability.Molecules (Basel, Switzerland) · 2025Article
- Design, fabrication and characterization of a magnetite-chitosan coated iron-based metal-organic framework (FeRSC advances · 2025Article
- MOFs for next-generation cancer therapeutics through a biophysical approach-a review.Frontiers in bioengineering and biotechnology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Beta-cyclodextrin Metal-Organic Framework (β-CD-MOF) is a unique class of porous materials that merges the inherent properties of cyclodextrins with the structural advantages of metal-organic frameworks (MOFs). When combined with the concept of MOFs, which are crystalline structures composed of metal ions or clusters linked by organic ligands, the resulting β-CD-MOF holds immense potential for various applications, especially in the field of drug delivery. In this study, biocompatible metal-organic frameworks (MOFs) synthesized using β-Cyclodextrin (β-CD) and potassium enabled drug delivery of curcumin (CCM) to cancerous cells. Functionalizing β-CD-MOF with l-glutamine (glutamine-β-CD-MOF) enhanced cancer cell-specific targeting due to glutamine's essential role in cancer cell proliferation and energy pathways. Amino group functionalization provided further functionalization opportunities. Gelatin coating (gelatin@β-CD-MOF) facilitated controlled drug release in an acidic medium. High drug loading capacities (52.38-55.63 %) were achieved for β-CD-MOF@CCM and glutamine-β-CD-MOF@CCM, leveraging the high porosity and affinity of amine and phenol groups of curcumin. The MTT assay highlighted the specificity and differentiation of glutamine-β-CD-MOF in targeting cancerous over normal cells. These functionalized β-CD MOFs efficiently encapsulate curcumin, ensuring controlled drug release and enhanced therapeutic efficacy, particularly in cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.